Verified factor-similar pair

UPGD vs XJH

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
86
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • XJH has the higher backtested relative Sharpe (0.705 vs 0.583).
  • XJH has the lower published fee (0.12% vs 0.40%).
  • UPGD is cheaper on dividend valuation (64 vs 117, where 100 is each fund's historical median).
  • XJH has the stronger regression fit (adjusted R-squared 0.942 vs 0.880).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

UPGD

Invesco Bloomberg Analyst Rating Improvers ETF
SMB
Adj. R2
0.880
Rel. Sharpe
0.583
Mkt beta
1.06
AUM
US$110M
MER
0.40%
Valuation
64

XJH

iShares ESG Select Screened S&P Mid-Cap ETF
SMB
Adj. R2
0.942
Rel. Sharpe
0.705
Mkt beta
1.02
AUM
US$362M
MER
0.12%
Valuation
117

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
UPGD
+0.65
|t|
+10.6
XJH
+0.54
|t|
+8.6
diff +0.11
HML
UPGD
+0.06
|t|
+1.1
XJH
+0.19
|t|
+3.2
diff -0.13
RMW
UPGD
+0.07
|t|
+0.9
XJH
+0.19
|t|
+2.9
diff -0.12
CMA
UPGD
+0.02
|t|
+0.2
XJH
-0.01
|t|
-0.1
diff +0.03
UMD
UPGD
-0.06
|t|
-1.7
XJH
+0.01
|t|
+0.2
diff -0.07

Why This Pair Matches

Exposure level
83
Exposure shape
97
Mkt beta diff
0.04
Rel. Sharpe diff
0.121

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

UPGD fund page XJH fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.